Ministry of Health (Kuwait)

LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20

Retrieved on: 
Wednesday, December 13, 2023
Ministry of Health (Kuwait), Ministry, Brain, Risk management, Amyloid-related imaging abnormalities, Disease, Risk, History, Patient, CET, Intraparenchymal hemorrhage, Eisai, MCI, Alzheimer's disease, Marketing, Horseshoe kidney, Co-promotion, Ageing, ARIA, Hypersensitivity, NHI, HIV disease progression rates, Lecanemab, Medical device, Pharmaceutical industry, Residential care, Biogen, Health

LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.

Key Points: 
  • LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.
  • The launch, planned for December 20, will make Japan the second country to have the product on the market, following the U.S.
    "This is a great Christmas present!
  • Alzheimer's disease patients in Japan will now have access to the first disease modifying treatment.
  • This gives hope for the large aging population in Japan with a great need for new treatment options," says Gunilla Osswald, CEO of BioArctic.

LEQEMBI® to be launched in Japan for Alzheimer's disease on December 20

Retrieved on: 
Wednesday, December 13, 2023
Ministry of Health (Kuwait), Ministry, Brain, Risk management, Amyloid-related imaging abnormalities, Disease, Risk, History, Patient, CET, Intraparenchymal hemorrhage, Eisai, MCI, Alzheimer's disease, Marketing, Horseshoe kidney, Co-promotion, Ageing, ARIA, Hypersensitivity, NHI, HIV disease progression rates, Lecanemab, Medical device, Pharmaceutical industry, Residential care, Biogen, Health

LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.

Key Points: 
  • LEQEMBI obtained manufacturing and marketing approval for the indication of slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in Japan on September 25, 2023.
  • The launch, planned for December 20, will make Japan the second country to have the product on the market, following the U.S.
    "This is a great Christmas present!
  • Alzheimer's disease patients in Japan will now have access to the first disease modifying treatment.
  • This gives hope for the large aging population in Japan with a great need for new treatment options," says Gunilla Osswald, CEO of BioArctic.

Regeneron Reports Third Quarter 2023 Financial and Operating Results

Retrieved on: 
Thursday, November 2, 2023
CSU, DLBCL, Bispecific monoclonal antibody, FDA, Adolescence, American College, Ageing, CD3, ESMO, Food, Multiple myeloma, CD20, Fast Track, ACG, Congress, European Society for Medical Oncology, DME, Symantec Endpoint Protection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American College of Gastroenterology, The Lancet, Ministry, Ministry of Health (Kuwait), CRL, MHLW, Ministry of Health, Labour and Welfare, Oncology, Sanofi, Safety, Atopic dermatitis, CSCC, European, Patient, BCMA, Chronic obstructive pulmonary disease, COPD, Dupilumab, BLA, Pharmaceutical industry, Medical device, Vaccine, C5, Regeneron Pharmaceuticals, Health, EU

"Our third quarter financial results reflect robust execution across the enterprise, including notable pipeline advances and strong commercial performance," said Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron.

Key Points: 
  • "Our third quarter financial results reflect robust execution across the enterprise, including notable pipeline advances and strong commercial performance," said Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron.
  • These results were also presented at the 23rd EURETINA Congress in October 2023.
  • The Company announced that Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron, will retire in February 2024.
  • Christopher Fenimore, current Senior Vice President, Head of Accounting and Controller at Regeneron, will succeed Mr. Landry as Chief Financial Officer upon his retirement.

Lunit Participates in Saudi Vision 2030 Healthcare Sandbox, Accelerating Saudi Arabia's Healthcare Transformation

Retrieved on: 
Thursday, October 26, 2023
MEA, Informatics, SVH, Innovation, Therapy, Gulf Cooperation Council, Memorandum of understanding, King Saud Medical City, Multimedia, Ministry of Health (Kuwait), Ministry, Partnership, Business, Hospital, CT, USD, Cancer, Tuberculosis, Movement, Patient, Diagnosis, Interior design, Pharmaceutical industry, Nursing, Health, Sandbox, Kingdom

Lunit's involvement in the Sandbox signifies a broader commitment to advancing the Saudi Arabian healthcare sector.

Key Points: 
  • Lunit's involvement in the Sandbox signifies a broader commitment to advancing the Saudi Arabian healthcare sector.
  • The Healthcare Sandbox, initiated by the Saudi Arabian Ministry of Health in line with the Saudi Vision 2030 strategy, is designed to facilitate the digital transformation of the Kingdom's healthcare industry.
  • As part of the Sandbox, Lunit will immediately sign a Memorandum of Understanding (MoU) with Seha Virtual Hospital (SVH).
  • Seha Virtual Hospital, the world's largest virtual hospital, is a key part of the Kingdom's healthcare transformation initiative, the cornerstone of the Saudi Vision 2030 strategy.

Trinity Biotech Announces Q2 2023 Financial Results

Retrieved on: 
Tuesday, October 3, 2023
KPI, Clinical chemistry, Federal Food, Drug, and Cosmetic Act, Partnership, Q3, SG, HIV, Diagnosis of HIV/AIDS, Reference, Balance sheet, Ion exchange, U.S. FDA, Mayo Clinic Center for Innovation, Ministry, A1C, EBITDA, Traction, Autoimmune disease, Supply chain, Investment, World Health Organization, Ministry of Health (Kuwait), Units of paper quantity, Growth, FDA, Calibration, Glycated hemoglobin, Pharmaceutical industry, Beauty salon, Fine chemical, Retail, Medical device, Video game, Vaccine, Renewable energy, Creative industries, Bank, Quest, Q2, Finance, Health, Sjögren syndrome, Diabetes

DUBLIN, Ireland, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended June 30, 2023.

Key Points: 
  • DUBLIN, Ireland, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended June 30, 2023.
  • Total revenue for fiscal Q2, 2023 was $13.9m (excluding Fitzgerald Industries, which was disposed of in April 2023).
  • In August, Trinity Biotech received U.S. FDA 510(k) clearance for the Premier Resolution System, the automated analyzer for accurate & precise quantification of haemoglobin variants.
  • Total revenues for Q2, 2023 were $13.9m which compares to $15.4m in Q2, 2022, a decrease of 9.8% and which were broken down as follows:

"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan

Retrieved on: 
Monday, September 25, 2023
Amyloid-related imaging abnormalities, PMID, Outline, Clinical trial, Marketing, The New England Journal of Medicine, Deficit spending, Pathology, Ministry of Health, Labour and Welfare, Research, Brain, Siderosis, History, MCI, The Different Forms of Flowers on Plants of the Same Species, Clarity, Ministry, ARIA, Dementia, HIV disease progression rates, Patient, Immunoglobulin G, Superficial siderosis, PLOS One, Co-promotion, Ministry of Health (Kuwait), Therapy, Headache, Neurotoxicity, Disease, ADCS, Pharmaceutical industry, Alzheimer's disease, Biogen, Amyloid beta, Health, Eisai

Japan is the second country to grant approval, following the traditional approval in the U.S. in July 2023.

Key Points: 
  • Japan is the second country to grant approval, following the traditional approval in the U.S. in July 2023.
  • In the Clarity AD clinical trial, treatment with LEQEMBI reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo.
  • "Today LEQEMBI received approval, making it the first approved anti-amyloid Alzheimer's disease treatment shown to reduce the rate of disease progression and to slow cognitive impairment in the early and mild dementia stages of the disease in Japan.
  • In Japan, Eisai and Biogen Japan will co-promote LEQEMBI, with Eisai distributing the product as the Marketing Authorization Holder.

Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Retrieved on: 
Friday, September 22, 2023
Conlon, CABG, Prevalence, Science Advances, Acute kidney injury, Oxygen, MOH, OTCQB, CPB, Arch, IRI, Inflammation, Ethics committee, AKI, Dialysis, Data monitoring committee, Cardiopulmonary bypass, Ministry, Ischemia, Investigational New Drug, Patient, TMX Group, Risk, Renal replacement therapy, Disease, Kidney, Ministry of Health (Kuwait), Reperfusion, Liver, Mortality, FDA, Food, Safety, National Research Council, Pharmaceutical industry, Hospital

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points: 
  • LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
  • This application in Turkey follows the Company’s submission of an Investigational New Drug Application to the U.S. Food and Drug Administration’s (FDA).
  • The FDA subsequently granted the Company permission to proceed with this Phase II trial in late June .
  • Of this total, the application to the MoH requests permission to recruit up to 150 patients in Turkey.

A report from People's Daily: PLA support base in Djibouti pursues peace, cooperation, friendship

Retrieved on: 
Tuesday, September 12, 2023
United Nations Security Council, People's Daily, Independence, Communication, Education, Face, Friends, Drainage, People's Liberation Army, Cataract, Sports equipment, Hope, Djibouti Ports & Free Zones Authority, Congo, Idle, Government, Fran, Ministry, National Association Medical Staff Services, Democratic republic, Patient, People's Liberation Army Support Base in Djibouti, Nursing, UN, United States Secretary of Labor, Ministry of Health (Kuwait), Growth, PLA, Ministry of Health, Liberation Army, Family, Moral and National Education controversy, Football, Vocation, Film industry, Shipbuilding, Drug, Health, Djibouti City, Balbala

The establishment of the PLA Djibouti base was a decision made by the two countries after friendly negotiations.

Key Points: 
  • The establishment of the PLA Djibouti base was a decision made by the two countries after friendly negotiations.
  • The PLA support base promotes mutual trust and understanding, and conveys a message of peace and friendship.
  • Since 2019, the PLA Support Base Hospital in Djibouti has partnered with the general hospital of Djibouti's military for paired assistance.
  • Ten medical staff members of the support base were awarded with the Independence Day Medal signed by President Ismail Omar Guelleh of Djibouti.

A report from People's Daily: PLA support base in Djibouti pursues peace, cooperation, friendship

Retrieved on: 
Tuesday, September 12, 2023
United Nations Security Council, People's Daily, Independence, Communication, Education, Face, Friends, Drainage, People's Liberation Army, Cataract, Sports equipment, Hope, Djibouti Ports & Free Zones Authority, Congo, Idle, Government, Fran, Ministry, National Association Medical Staff Services, Democratic republic, Patient, People's Liberation Army Support Base in Djibouti, Nursing, UN, United States Secretary of Labor, Ministry of Health (Kuwait), Growth, PLA, Ministry of Health, Liberation Army, Family, Moral and National Education controversy, Football, Vocation, Film industry, Shipbuilding, Drug, Health, Djibouti City, Balbala

The establishment of the PLA Djibouti base was a decision made by the two countries after friendly negotiations.

Key Points: 
  • The establishment of the PLA Djibouti base was a decision made by the two countries after friendly negotiations.
  • The PLA support base promotes mutual trust and understanding, and conveys a message of peace and friendship.
  • Since 2019, the PLA Support Base Hospital in Djibouti has partnered with the general hospital of Djibouti's military for paired assistance.
  • Ten medical staff members of the support base were awarded with the Independence Day Medal signed by President Ismail Omar Guelleh of Djibouti.

Global Times: PLA support base in Djibouti pursues peace, cooperation, friendship

Retrieved on: 
Monday, September 11, 2023
United Nations Security Council, People's Daily, Independence, Communication, Education, Face, Friends, Drainage, Cataract, Sports equipment, Hope, Djibouti Ports & Free Zones Authority, Congo, Idle, Government, Fran, Ministry, National Association Medical Staff Services, Democratic republic, Patient, Moral and National Education controversy, People's Liberation Army Support Base in Djibouti, Nursing, UN, United States Secretary of Labor, Ministry of Health (Kuwait), Growth, PLA, Ministry of Health, Liberation Army, Army Command College of the Chinese People's Liberation Army, Family, Football, Vocation, Film industry, Shipbuilding, Drug, Health, Djibouti City, Balbala

The establishment of the PLA Djibouti base was a decision made by the two countries after friendly negotiations.

Key Points: 
  • The establishment of the PLA Djibouti base was a decision made by the two countries after friendly negotiations.
  • The PLA support base promotes mutual trust and understanding, and conveys a message of peace and friendship.
  • Since 2019, the PLA Support Base Hospital in Djibouti has partnered with the general hospital of Djibouti's military for paired assistance.
  • Ten medical staff members of the support base were awarded with the Independence Day Medal signed by President Ismail Omar Guelleh of Djibouti.